Clinicopathology of sialomucin: MUC1, particularly KL-6 mucin, in gastrointestinal, hepatic and pancreatic cancers.
Yoshinori Inagaki(Yokohama University of Pharmacy), Norihiro Kokudo(National Center for Global Health and Medicine), Wei Tang(National Center for Global Health and Medicine), Yasuji Seyama(Hakodate Central General Hospital), Huanli Xu(Capital Medical University), Yasuhiko Sugawara(Kumamoto University), Munehiro Nakata(Tokai University), Kiyoshi Hasegawa(Bunkyo University)
PubMed
December 1, 2009
Cited by 45
Related Papers
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2019|2k
Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy
|Journal of Hepatology|2003|1.6k
Trans-ancestry mutational landscape of hepatocellular carcinoma genomes
|Nature Genetics|2014|780